Shuttle Pharmaceuticals Obtains U.S. Patent

Brief Summary

Shuttle Pharmaceuticals has secured a US patent for selective histone deacetylase inhibitors aimed at improving cancer treatment outcomes.

Impact of The News

Introduction

Shuttle Pharmaceuticals, a specialty pharmaceutical company based in Gaithersburg, Maryland, was granted a US patent on September 3, 2024, for selective histone deacetylase inhibitors, which are intended for treating human diseases, particularly to enhance the prognosis of cancer patients undergoing radiotherapy.

Level of Impact

• Level: Company and Product
• Domain: Biotechnology/Pharmaceuticals

Impact Transmission Path

• Company Impact:

• Strengthened Intellectual Property: This patent fortifies Shuttle Pharmaceuticals’ intellectual property portfolio, enhancing its competitive edge in the oncology sector by providing protection and exclusivity in developing HDAC inhibitors.

• Increased Investment Appeal: The patent may attract investors interested in innovative cancer therapies, potentially leading to increased funding opportunities for Shuttle Pharmaceuticals.

• Product Impact:

• Enhanced R&D Focus: With secure intellectual property, the company can focus its research and development efforts on further developing and commercializing its HDAC inhibitors, potentially accelerating product development timelines.

• Collaboration Opportunities: The patent could open doors for strategic partnerships or collaborations with other pharmaceutical companies seeking to enhance their cancer treatment portfolios.

Overall, the acquisition of this patent positions Shuttle Pharmaceuticals as a more formidable player in the biotechnology field, potentially impacting its market presence and future revenue streams.